Clinical trial
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis…
NCT00106184 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00106184 |
|---|---|
| Title | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) |
| Official title | Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIH Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis |
| Intervention type | Drug |
| Interventions | Rituximab, Placebo |
| Enrollment | 200 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Mar 22, 2005 |
| Last update posted | Mar 4, 2015 |
| Countries | Canada, Czechia, Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: